Access
To read this story in full you will need to login or make a payment (see right).
Insight
Nature 446, 1038-1045 (26 April 2007) | doi:10.1038/nature05818; Published online 25 April 2007
Open Innovation Challenges
- More Challenges
- Powered by:
nature jobs
Junior Research Groups (W1 / W2)
- Cluster of Excellence "Multimodal Computing and Interaction"
- Saarbruecken Germany
Professor of Experimental Virology (W3)
- University Hospital Jena, Institute of Virology and Antivirale Therapy
- Jena, Germany
Exploiting the defensive sugars of HIV-1 for drug and vaccine design
Christopher N. Scanlan1, John Offer2, Nicole Zitzmann1 & Raymond A. Dwek1
Abstract
The sustained effort towards developing an antibody vaccine against HIV/AIDS has provided much of our understanding of viral immunology. It is generally accepted that one of the main barriers to antibody neutralization of HIV is the array of protective structural carbohydrates that covers the antigens on the virus's surface. Intriguingly, however, recent findings suggest that these carbohydrates, which have evolved to protect HIV and promote its transmission, are also attractive therapeutic targets.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
EDEM an ER quality control receptorNature Structural Biology News and Views (01 May 2003)
Mass spectrometry provides sweet inspirationNature Biotechnology News and Views (01 Jun 2003)
Seeing cellular sialidase transform sugarsNature Chemical Biology News and Views (01 Dec 2008)
HIV-1: nature's master of disguiseNature Medicine News and Views (01 Apr 2003)
Glycome 'fingerprints' provide definitive clues to HIV originsNature Chemical Biology News and Views (01 Apr 2009)
